Ensysce Biosciences (ENSC) Shares Outstanding (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Shares Outstanding (Entity) of $2.6 million for Q4 2025, up 266.55% year-over-year from $697686.0 in Q4 2024, and down 19.61% quarter-over-quarter from $3.2 million in Q3 2025.
Ensysce Biosciences (ENSC) Shares Outstanding (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Shares Outstanding (Entity) for 9 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 266.55% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (up 266.55% YoY), while the FY2025 annual figure was $2.6 million, up 266.55% from the prior year.
- Shares Outstanding (Entity) fell to $2.6 million in Q4 2025 per ENSC's latest filing, from $3.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $3.2 million in Q3 2025 and bottomed at $1729.0 in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $635387.2 across 5 years, with a median of $164470.0 in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) tumbled 60.82% — and 2023, when it soared 1703.39%.
- Ensysce Biosciences' Shares Outstanding (Entity) stood at $5601.0 in 2021, then soared by 114.18% to $11996.0 in 2022, then surged by 1158.29% to $150945.0 in 2023, then surged by 362.21% to $697686.0 in 2024, then surged by 266.55% to $2.6 million in 2025.
- Business Quant data shows ENSC's Shares Outstanding (Entity) at $2.6 million in Q4 2025, $3.2 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 697,686.00 |
| Sep 30, 2024 | 659,392.00 |
| Jun 30, 2024 | 587,850.00 |
| Mar 31, 2024 | 379,650.00 |
| Dec 31, 2023 | 150,945.00 |
| Sep 30, 2023 | 205,735.00 |
| Jun 30, 2023 | 151,615.00 |
| Mar 31, 2023 | 70,284.00 |
| Dec 31, 2022 | 11,996.00 |
| Sep 30, 2022 | 10,715.00 |
| Jun 30, 2022 | 9,441.00 |
| Mar 31, 2022 | 7,580.00 |
| Dec 31, 2021 | 5,601.00 |
| Sep 30, 2021 | 6,738.00 |
| Jun 30, 2021 | 4,459.00 |
| Mar 31, 2021 | 1,729.00 |